|
Mixed Results Eyed for Generics’ Attacks on Shire ADHD Franchise
Wall Street analysts predict Actavis’ ANDA on attention-deficit hyperactivity disorder (ADHD) drug Intuniv won’t infringe Shire’s patents, and the generic-drug maker could launch as soon as October if it wins approval.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives